The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...

A new study from Huashan Hospital, Shanghai, provided strong evidence supporting the efficacy and safety of abrocitinib for ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...

Jason B. Pieper, DVM, MS, DACVD, talks about the multiple therapies available for cases of moderate and severe atopic ...

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

Clinical Care Options in collaboration with the National Eczema Association is hosting an innovative and engaging symposium IL-13 Inhibition in Moderate to Severe Atopic Dermatitis: A Clinical Skills ...

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.